发布求助
文献互助 智能选刊 最新文献

Cancer chemotherapy reports最新文献

筛选
英文 中文
PORFIROMYCIN.
Cancer chemotherapy reports Pub Date : 2020-02-07 DOI: 10.32388/qo0a9x
L. Duvall
{"title":"PORFIROMYCIN.","authors":"L. Duvall","doi":"10.32388/qo0a9x","DOIUrl":"https://doi.org/10.32388/qo0a9x","url":null,"abstract":"An N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species. Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis. Porfiromycin is preferentially toxic to hypoxic cells. (NCI04)","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83056913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment of small cell carcinoma of the lung using methyl-CCNU (NSC-95441) combined with cyclophosphamide (NSC-26271) and vincristine (NSC-67574) in a 3-week schedule. 甲基- ccnu (NSC-95441)联合环磷酰胺(NSC-26271)和长春新碱(NSC-67574)治疗肺小细胞癌，为期3周。
Cancer chemotherapy reports Pub Date : 1975-11-01
S G Taylor, M A Donavan, R W Sponzo, T J Cunningham, J Horton
{"title":"Treatment of small cell carcinoma of the lung using methyl-CCNU (NSC-95441) combined with cyclophosphamide (NSC-26271) and vincristine (NSC-67574) in a 3-week schedule.","authors":"S G Taylor,&nbsp;M A Donavan,&nbsp;R W Sponzo,&nbsp;T J Cunningham,&nbsp;J Horton","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Twenty-six patients with small cell carcinoma of the lung were treated with a combination of methyl-CCNU (75 mg/m2 orally), cyclophosphamide (750 mg/m2iv), and vincristine (1.4 mg/m2iv) once every 3 weeks and followed for 2-56 weeks (mean, 24 weeks). An average of seven treatments were given per patient. Myelotoxicity was mild to moderate with no white blood cell count (wbc) less than 1000 cells/mm3 and no platelet count less than 25,000 cells/mm3. Six patients (23%) had a wbc of 1000-2000 cells/mm3 and two (8%) had a platelet count of 25,000-75,000 cells/mm3. Sixty-eight persons of the projected dose of methyl-CCNU was given. Fourteen of 22 patients with measurable disease (54%) responded. Of 14 patients who had received no prior treatment 64% responded with a median survival duration of 40 weeks. Complete responses occurred only in patients without prior radiation therapy or chemotherapy. We conclude that methyl-CCNU may be given with an acceptable level of toxicity in an every 3-week schedule and that the combination of cyclophosphamide, methyl-CCNU, and vincristine warrants further evaluation in the treatment of small cell carcinoma of the lung.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma. 依美汀(NSC-33669)治疗表皮样支气管癌的I-II期评价
Cancer chemotherapy reports Pub Date : 1975-11-01
R C Kane, M H Cohen, L E Broder, M I Bull, P J Creaven, B E Fossieck
{"title":"Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.","authors":"R C Kane,&nbsp;M H Cohen,&nbsp;L E Broder,&nbsp;M I Bull,&nbsp;P J Creaven,&nbsp;B E Fossieck","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12398680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methyl-CCNU (NSCU-95441) versus methyl-CCNU plus cyclophosphamide (NSC-26271) in advanced gastrointestinal cancer. 甲基- ccnu (NSCU-95441)与甲基- ccnu +环磷酰胺(NSC-26271)在晚期胃肠癌中的作用。
Cancer chemotherapy reports Pub Date : 1975-11-01
A Rossi, A Riva, G Bonadonna
{"title":"Methyl-CCNU (NSCU-95441) versus methyl-CCNU plus cyclophosphamide (NSC-26271) in advanced gastrointestinal cancer.","authors":"A Rossi,&nbsp;A Riva,&nbsp;G Bonadonna","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease. 博莱霉素(NSC-125066)和CCNU (NSC-79037)在耐mopp霍奇金病联合化疗中的应用
Cancer chemotherapy reports Pub Date : 1975-11-01
J E Kurnick, M White, D E Ware, W A Robinson
{"title":"Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.","authors":"J E Kurnick,&nbsp;M White,&nbsp;D E Ware,&nbsp;W A Robinson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Twenty-two patients with MOPP-resistant stage IVB Hodgkin's disease were treated with a combination of bleomycin and CCNU. The response rate in 18 patients surviving at least 1 month was 72% with 11 partial and two complete responses. The mean duration of response and survival in partial responders were 12.2 and 17.5 months respectively. The two complete responses resulted in survivals of 20 and 36 + months. Bleomycin toxicity contributed to two deaths, one pulmonary and and one hypotensive. Severe CCNU toxicity occurred after three of 82 administrations but there were no CCNU-related deaths. The majority of patients in the study tolerated the regimen without serious toxicity. Although highly effective in the temporary control of advanced resistant Hodgkin's disease, the program will hopefully be improved by the addition of longer-acting agents.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11279704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination chemotherapy for acute nonlymphoblastic leukemia in adults. 成人急性非淋巴细胞白血病的联合化疗。
Cancer chemotherapy reports Pub Date : 1975-11-01
H Glucksberg, C D Buckner, A Fefer, Q DeMarsh, D Coleman, R B Dobrow, J Huff, C Kjobech, A S Hill, W Dittman, P E Neiman, M A Cheever, A B Einstein, E D Thomas
{"title":"Combination chemotherapy for acute nonlymphoblastic leukemia in adults.","authors":"H Glucksberg,&nbsp;C D Buckner,&nbsp;A Fefer,&nbsp;Q DeMarsh,&nbsp;D Coleman,&nbsp;R B Dobrow,&nbsp;J Huff,&nbsp;C Kjobech,&nbsp;A S Hill,&nbsp;W Dittman,&nbsp;P E Neiman,&nbsp;M A Cheever,&nbsp;A B Einstein,&nbsp;E D Thomas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Between January 1973 and February 1975, 77 adults with acute nonlymphoblastic leukemia were treated with a combination of daunorubicin, cytosine arabinoside, 6-thioguanine, prednisone, and vincristine in university-affiliated and private institutions. After 31 patients were treated (regimen 1) the doses of all drugs were significantly increased (regimen 2). Regimes 1 and 2 yielded CR rates of 59% (17 of 29 patients) and 70% (32 of 46 patients) respectively. With regimens 2 the mean number of courses and the median number of days to CR decreased from 3 to 1.4 and from 46 to 29 respectively. Failure to achieve CR was due to persistent leukemia during regimen 1 and fatal infections during regimen 2. With regimen 2 ten of 20 patients (50%) greater than 50 years had CR compared to 22 of 26 patients (85%) less than 50 years. CR rates were similar in community and university institutions.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt's lymphoma. CCNU (NSC-79037)用于预防Burkitt淋巴瘤累及中枢神经系统的评估。
Cancer chemotherapy reports Pub Date : 1975-11-01
J L Ziegler, I T Magrath, F K Nkrumah, I V Perkins, R Simon
{"title":"Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt's lymphoma.","authors":"J L Ziegler,&nbsp;I T Magrath,&nbsp;F K Nkrumah,&nbsp;I V Perkins,&nbsp;R Simon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors. 环磷酰胺(NSC-26271)、阿拉伯糖胞嘧啶(NSC-63878)和甲氨蝶呤(NSC-740)联合化疗治疗晚期实体瘤。
Cancer chemotherapy reports Pub Date : 1975-11-01
O O Odujinrin, R C DeConti, J R Bertino
{"title":"Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.","authors":"O O Odujinrin,&nbsp;R C DeConti,&nbsp;J R Bertino","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Forty patients with advanced solid tumors of diverse primary sites received a combination of cyclophosphamide (1 gm/m2), cytosine arabinoside (300 mg/m2), and methotrexate (80 mg/m2) given intermittently at 2-3-week intervals. Eight of the 40 patients received citrovorum factor rescue. The major limitation of therapy was suppression of bone marrow elements. Only minimal nonhematologic toxicity was encountered. Granulocytes appeared the most sensitive. The first course of treatment produced median nadir granulocyte and platelet counts of 1200 and 100,000 cells/mm3 respectively. Subsequent courses were tolerated with no evidence of increasing myelosuppression. Objective antitumor responses were noted in five of 16 patients with lung cancer and in eight of 14 women with breast cancer with a median duration of 8 months.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. 5-氮杂胞苷(NSC-102816)的I期研究，24小时连续输注5天。
Cancer chemotherapy reports Pub Date : 1975-11-01
P L Lomen, L H Baker, G L Neil, M K Samson
{"title":"Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.","authors":"P L Lomen,&nbsp;L H Baker,&nbsp;G L Neil,&nbsp;M K Samson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The biologic and antitumor activity of 5-azacytidine has been well demonstrated in the past. The drug at present is thought to be primarily cell cycle phase specific. This study was designed to eliminate undesirable side effects (mainly nausea and vomiting) occurring with a bolus dose and to confirm the recent findings of the relative stability of 5-azacytidine's solution with preserved biologic and antitumor activity. In the study we determined that a dose of 150 mg/m2/day given as a 120-hour continuous iv infusion and repeated at 28-day intervals produced safe, manageable, and reproducible toxicity. The drug was freshly prepared at 4-hour intervals. Eleven courses were administered to seven patients at this dose level and no patient experienced nausea or vomiting. Leukopenia was the major toxic effect. Antitumor activity was shown in one patient with colon cancer and another with American Burkitt's lymphoma.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11278839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma. 5-氟尿嘧啶(NSC-19893)、甲氨蝶呤(NSC-740)和强的松龙(NSC-9900) (FAP方案)联合化疗治疗肝癌。
Cancer chemotherapy reports Pub Date : 1975-11-01
T Umsawasdi, T Chainuvati, S Hitannant, P Nilprabhassorn, V Viranuvatti
{"title":"Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma.","authors":"T Umsawasdi,&nbsp;T Chainuvati,&nbsp;S Hitannant,&nbsp;P Nilprabhassorn,&nbsp;V Viranuvatti","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11395104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信